Clinical trials: SCHIZOPHRENIA 1 (Disorder)
Schizophrenia
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
- Trial name
- NCT01879722
- Testing
- TAK-063
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Takeda
Coronary Disease, Myocardial Infarction
Chronical Illness-related Limitations of the Ability to Cope with Rising Temperatures: an Observational Study, 2nd Wave
The CLIMATE-II Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health behavior, somatosensory amplification, risk and…
- Conditions
- Coronary Disease, Myocardial Infarction, Heart Failure, Arrhythmias, Cardiac
- Trial name
- CLIMATE-II (NCT06407154)
- Where
- Germany
- Volunteers
- 578 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation
The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia
The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Psychosocial Adaptation, Treatment Adherence
- Trial name
- NCT07144592
- Testing
- solution-oriented approach program
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Muş Alparslan University
Schizophrenia
Study of CAD-9303 in Subjects With Schizophrenia
This study will consist of Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts that will be randomized, double-blind, and placebo-controlled to assess the safety, tolerability, and pharmacokinetics of CAD-9303.
- Trial name
- Affinity-1 (NCT04306146)
- Testing
- CAD-9303
- Where
- 2 sites in United States
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Cadent Therapeutics
Schizophrenia
A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women
The purpose of this study is to assess the effect of cytochrome P450 isoenzyme 2D6 (CYP2D6) inhibition by quinidine on the pharmacokinetic (PK) parameters of a single dose SEP-380135 in healthy adult participants.
- Trial name
- NCT07305779
- Testing
- SEP-380135, Quinidine Gluconate
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Potential Intervention Strategy With Folic Acid and Vitamin B12 in Patients With Schizophrenia
The investigators study aims are: 1. To investigate folate, vitamin B12, and homocysteine levels in patients with schizophrenia. 2.
- Trial name
- NCT02916121
- Testing
- folic acid 5 mg/cap
- Where
- Taiwan
- Volunteers
- 88 people
- Sponsor
- Taipei Medical University WanFang Hospital
Schizophrenia
A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
A study to evaluate the safety, tolerability, and PK of an injectable form of KarXT in participants with schizophrenia
- Trial name
- NCT07061288
- Testing
- KarXT
- Where
- 8 sites in United States
- Volunteers
- 131 people
- Sponsor
- Bristol-Myers Squibb
Schizophrenia
A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia
The purpose of this study is a noninferiority comparison of the orthostatic tolerability of a dose of 12 mg extended-release (ER) OROS paliperidone with the current recommended initial titration dose (2 mg) of immediate-release…
- Trial name
- NCT00791232
- Testing
- extended-release (ER) OROS paliperidone
- Volunteers
- 113 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia
Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
The Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services (BICEPS) study aims to understand the early stages of psychotic disorders like Schizophrenia, Schizoaffective Disorder, and Bipolar I Disorder.
- Conditions
- Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Delusional Disorder, Bipolar 1 Disorder
- Trial name
- BICEPS (NCT06740383)
- Where
- 6 sites in United States
- Volunteers
- 320 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia
Comparative Bioavailability of Risperidone
This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia…
- Trial name
- NCT03527186
- Testing
- Risperidone ISM® 100 mg
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Schizophrenia
Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia
The purpose of the study is to investigate these effects of Second-Generation Antipsychotic (SGAs) on glucose and lipid metabolic parameters in patients with schizophrenia, and explore the relationship between genes polymorphisms…
- Trial name
- NCT02964923
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital
Schizophrenia, Autism
Lurasidone Pediatric Pharmacokinetics Study
This is a Phase 1, open-label, multicenter, single and multiple ascending lurasidone dose study in subjects from 6 to 17 years old with schizophrenia spectrum, bipolar spectrum, autistic spectrum disorder, or other psychiatric…
- Trial name
- NCT01620060
- Testing
- Lurasidone
- Where
- 10 sites in United States
- Volunteers
- 105 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
- Trial name
- NCT01900522
- Testing
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia
Primary Objective: To evaluate the safety and tolerability of single doses of TV-44749 for subcutaneous (sc) use in Chinese participants with schizophrenia.
- Trial name
- NCT06253546
- Testing
- TV-44749 318mg, Oral Olanzapine 10mg/day, TV-44749 425mg
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.
- Conditions
- Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult
- Trial name
- CNTRACS (NCT07900893)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients
The purpose of this study is to evaluate the effects of nicotinic alpha-7 MEM 3454 on P50 sensory gating in patients with Schizophrenia. The hypothesis is that MEM 3454 will normalize the P50 ratio.
- Trial name
- P50 (NCT00725855)
- Testing
- MEM 3454
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Memory Pharmaceuticals
Parenting, Psychosis
Understanding and Helping Families: Parents With Psychosis
The purpose of this trial is to explore parent-child interactions in parents with and without psychosis, and ascertain whether a brief (10 week) supported self-help parenting program offered to parents in their own homes can help…
- Conditions
- Parenting, Psychosis, Schizophrenia
- Trial name
- NCT02622048
- Testing
- Triple P Positive Parenting Programme
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Psychotic Disorder, SCHIZOPHRENIA 1 (Disorder)
Ultrasound Assessment of Gluteal Muscle in Patients Receiving Depot Antipsychotics and Healthy Volunteers
This observational study will use ultrasound to assess the gluteal musculature in patients receiving depot antipsychotic medication and in healthy volunteers.
- Conditions
- Psychotic Disorder, SCHIZOPHRENIA 1 (Disorder), Intramuscular Injection
- Trial name
- ULPSYK (NCT07815587)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- St. Olavs Hospital
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 1
The investigators are modifying and testing the preliminary effectiveness and implementation of a Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) intervention.
- Trial name
- NCT04689867
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan